Future therapeutics for osteoarthritis.
Osteoarthritis (OA) is a disease of the joints that affects several million individuals worldwide. This disease, which involves mainly the diarthrodial joints, is chronic and develops slowly over decades, making it very difficult to precisely identify the different etiological and risk factors that influence its onset. At present, most therapies for OA are symptomatic. This review will focus on new OA therapeutics in development that are directed toward pain relief as well as others with the potential to reduce or stop the progression of the disease (DMOADs). This article is part of a Special Issue entitled "Osteoarthritis".
Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, Quebec, Canada. jm@martelpelletier.ca
Johanne
J
Martel-Pelletier
Lukas M
LM
Wildi
Jean-Pierre
JP
Pelletier
D018501:Antirheumatic Agents / Q000627:therapeutic use*; D035843:Biomedical Research; D016723:Bone Remodeling / Q000187:drug effects; D006801:Humans; D007249:Inflammation / Q000150:complications / Q000188:drug therapy / Q000473:pathology; D010003:Osteoarthritis / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D013583:Synovial Membrane / Q000187:drug effects / Q000473:pathology
D018501:Antirheumatic Agents